Tucatinib 150mg placebo tablets
Sponsors
Seagen Inc.
Conditions
Unresectable locally-advanced or metastatic HER2+ breast cancer
Phase 3
A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)
Active, not recruitingCTIS2023-503826-37-00
Start: 2022-02-11Target: 249Updated: 2026-01-08
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)
Active, not recruitingCTIS2024-514733-38-00
Start: 2020-11-03Target: 101Updated: 2025-10-20